Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
STU:AS00's 14-Day RSI is ranked better than 98.03% of 1424
companies
in the Biotechnology industry
Industry Median: 47.285
vs STU:AS00: 22.33
European Medical Solutions (STU:AS00) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
European Medical Solutions 14-Day RSI Related Terms
STU:AS00 vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, European Medical Solutions's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's 14-Day RSI falls into.
European Medical Solutions (STU:AS00) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
European Medical Solutions (STU:AS00) has a 14-Day RSI of 22.33 as of Jul. 18, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on European Medical Solutions and its competitors. According to the industry distribution chart, European Medical Solutions ranks #28 out of 1424 companies in the Biotechnology industry, placing it in the top 2%.
Is European Medical Solutions' 14-Day RSI too high?
European Medical Solutions' current 14-Day RSI is 22.33. The Biotechnology industry median 14-Day RSI is 47.29. European Medical Solutions' value of 22.33 is 52.8% below this industry median. Based on the distribution chart, European Medical Solutions ranks #28 out of 1424 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, European Medical Solutions has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #28 out of 1424 companies for 14-Day RSI. This places European Medical Solutions in the top 2% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 47.29. European Medical Solutions' value of 22.33 is 52.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 47.29, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. European Medical Solutions's current 14-Day RSI of 22.33 is 52.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on European Medical Solutions and its competitors. For the Biotechnology industry, the median 14-Day RSI is 47.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. European Medical Solutions's current 14-Day RSI is 22.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current 14-Day RSI of 22.33. The stock's GF Value™ is €8.16, compared to a current price of €3.98 — trading 51.2% below its estimated fair value. The current 14-Day RSI is 22.33 and 52.8% below the Biotechnology industry median of 47.29. European Medical Solutions' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current 14-Day RSI is 22.33 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €3.98 is trading 51.2% below its estimated GF Value™ of €8.16.
Key valuation signals for STU:AS00:
14-Day RSI: 22.33
GF Value™: €8.16 vs. price of €3.98 (51.2% below fair value)
Industry Position: 52.8% below the Biotechnology median (#28 of 1424)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
43GF Score
Get the complete analysis for STU:AS00
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
